Combinations of tumor-associated antigens in diagnostics for various types of cancers
AssigneeMannKind Corporation
InventorsChih-Sheng CHIANG, John J.L. SIMARD
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for confirming diagnosis of a particular type of cancer. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs to optimize the match between a patient's cancer condition and available immunotherapies.
Claims39
A method of matching a cancer condition in a patient with an immunotherapeutic regimen, comprising the steps of:
- assaying the patient's tumor tissue for two or more expressed tumor-associated antigens (TuAAs) in a preselected panel, wherein the two or more TuAAs include an antigen expressed by a tumor-associated stromal cell, to develop an antigen profile for the tumor;
- and
- selecting an immunotherapeutic regimen based on the profile, the regimen comprising administration of one or more immunotherapeutic agents, wherein said one or more immunotherapeutic agents are available on the market on in clinical trials, and wherein said one or more immunotherapeutic agents target two or more antigens in the profile.
A method of matching a cancer condition in a patient with an immunotherapeutic agent, comprising the steps of:
- determining the patient's class I MHC type;
- assaying the patient's tumor tissue for two or more expressed tumor-associated antigens (TuAAs) in a preselected panel;
- assaying the patient's tumor tissue for the expression of MHC class I or β2-microglobulin;
- selecting an immunotherapeutic agent for administration to the patient based on the assays, wherein the immunotherapeutic agent comprises or encodes an epitope restricted by the patient's class I MHC type, for each of two or more antigens expressed by the tumor.
A method of confirming a cancer diagnosis comprising the steps of:
- assaying a patient's tumor tissue to detect one or more expressed polypeptides in a preselected panel, wherein the panel comprises two or more TuAAs and at least one lineage marker, to develop an expression profile for the tumor;
- and
- confirming a cancer diagnosis based upon the expression profile.
A method of matching a cancer condition in a patient with an immunotherapeutic agent, comprising the steps of:
- assaying tumor tissue of the patient for two or more expressed tumor-associated antigens (TuAAs) in a preselected panel, to develop an antigen profile for the tumor;
- and
- selecting an immunotherapeutic agent for the patient based on the profile, wherein the immunotherapeutic agent targets one or more of the expressed antigens in the profile.
Dependencies are inferred from the claim text.